Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 340-348

  Oestreich, J H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; ELINOGREL; PRASUGREL; PRT 060128; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; PURINERGIC P2 RECEPTOR; QUINAZOLINONE DERIVATIVE; SULFONAMIDE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IC 50; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ANTAGONISM;

ACUTE CORONARY SYNDROME; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; QUINAZOLINONES; RECEPTORS, PURINERGIC P2; SULFONAMIDES; THROMBOSIS;

EID: 77649165959     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. The effect of prescribed daily dose frequency on patient medication compliance. Eisen SA, Miller DK, Woodward RS, Spitanagel E, Przybeck TR ARCH INTERN MED 1990 150 9 1881-1884
2. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Hollopeter G, Janzten HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB NATURE 2001 409 6817 202-207 (Pubitemid 32144286)
3. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L EUR HEART J 2006 27 10 1166-1173
4. A novel pharmacodynamic perfusion chamber assay reveals superior and unique antithrombotic activities of a directacting P2Y12 antagonist, PRT128, relative to clopidogrel. Conley P, Jurek M, Stephens G, He M, Finn A, Gold H, Romanko K, Gretler D, Phillips D, Andre P BLOOD 2006 108 11 Abs 900
5. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK N ENGL J MED 2001 345 7 494-502
6. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM Circulation 2003 107 23 2908-2913
7. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jaknbowski JA, Naganuma H, Winters KJ AM HEART J 2007 153 1 66.e9-66.e16
8. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ JAMA-J AM MED ASSOC 2002 288 19 2411-2420
9. NCT00546260: Safety and efficacy study of adjunctive antiplatelet therapy prior to primary percutaneous intervention in patients with ST-elevation myocardial infarction (ERASE-MI). Portola Pharmaceuticals clinicaltrials.gov 2007 November 26
10. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F, Ardissino D, De Servi S, Murphy SA, Riesmeyer J et al N ENGL J MED 2007 357 20 2001-2015 (Pubitemid 350106708)
11. Prasugrel achieves greater and faster P2Y12 receptormediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Wallentin L, Varenhorst C, James S, Erlinge D, Braun O, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A EUR HEART J 2008 29 1 21-30
12. Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Gurbel PA, Tantry US CURR OPIN INVESTIG DRUGS 2008 9 3 324-336
13. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS THROMB RES 2008 121 4 527-534
14. Development of a direct-acting reversible P2Y12 antagonist. Conley PB AM CHEM SOC NATL MEET EXPOSITION 2008 236 Abs Medi-235
15. Combination of direct acting FXa inhibitor and P2Y12 antagonist at non-effective doses provides significant inhibition of arterial thrombosis. Andre P, Conley PB, Deguzman F, Pak Y, Inagaki M, Sinha U, Phillips DR CIRCULATION 2008 118 Suppl Abs 1718
16. Oral dosing of PRT060128, a novel direct-acting, reversible P2Y12 antagonist overcomes high platelet reactivity in patients non-responsive to clopidogrel therapy. Gurbel PA, Conley PB, Andre P, Stephens G, Gretler DD, Jurek MM, Bliden KP, Antonino MJ, Singla A, Suarez T, Tantry US AM HEART ASSOC SCIENTIFIC SESSIONS 2008 November 12 Abs 5603
17. Portola Pharmaceuticals initiates phase II trial of novel IV and oral anti-platelet drug in non-urgent percutaneous coronary intervention. Portola Pharmaceuticals Inc PRESS RELEASE 2008 December 09
18. Cytochrome P-450 polymorphisms and response to clopidogrel. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS N Engl J Med 2009 360 4 354-362
19. Portola Pharmaceuticals enters worldwide license agreement for development and commercialization of novel antiplatelet drug elinogrel. Portola Pharmaceuticals Inc PRESS RELEASE 2009 February 12
20. Novartis gains worldwide rights to elinogrel, a phase II anti-clotting compound with potential to reduce risk of heart attack and stroke. Novartis AG PRESS RELEASE 2009 February 12
21. European Commission approves Efient (prasugrel) for patients with acute coronary syndrome undergoing PCI. Eli Lilly & Co, Daiichi Sankyo Co Ltd PRESS RELEASE 2009 February 23
22. Identification of nonsulfonylurea P2Y12 inhibitors as a follow-up series to PRT060128. Bauer SM, Mehrotra MM, Venkataraman M, Conley PB, Jurek M, Hutchaleelaha A, Ye C, Hollenbach S, Scarborough R, Pandey A AM CHEM SOC NATL MEET EXPOSITION 2009 237 Abs MEDI-07
23. Ticlopidine and clopidogrel. Quinn MJ, Fitzgerald DJ CIRCULATION 1999 100 15 1667-1672
24. First launch of Efient worldwide takes place in the UK. Daiichi Sankyo Co Ltd PRESS RELEASE 2009 April 08
25. American Chemical Society-237th National Meeting & Exposition. Part 1. Veryard C IDrugs 2009 12 5 265-268
26. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. Doggrell SA IDrugs 2009 12 5 309-317
27. The top 10 causes of death. World Health Organization COMPANY PRESENTATION 2009 June 14
28. Heart disease and stroke statistics 2009 update at-a-glance. American Heart Association INTERNET SITE 2009 April 20
29. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP BLOOD 2003 101 10 3908-3914
30. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC AM J CARDIOL 2004 93 4 456-458
31. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ THROMB HAEMOST 2008 99 1 215-222
32. Effient is now available in pharmacies. Eli Lilly & Co PRESS RELEASE 2009 August 05
33. Cangrelor: Phase III clinical trials. The Medicines Company COMPANY WORLD WIDE WEB SITE 2009 August 24
34. Novel antiplatelet therapies following percutaneous coronary interventions. Ahrens I, Bode C CURR OPIN INVESTIG DRUGS 2009 10 9 902-911
35. Cardiovascular diseases. Fact sheet No 317. World Health Organization INTERNET SITE 2009 September 12
36. Portola Pharmaceuticals company website and pipeline. Portola Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2009 September 01
37. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW et al N ENGL J MED 2009 361 11 1045-1057
38. "First in human" experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for iv and oral use. Gretle DD, Conley PB, Andre P, Jurek M, Pandey A, Romanko K, Leese PT, Hutchaleelaha A, Phillips DR J AM COLL CARDIOL 2007 49 9 Abs 1002-1128
39. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C19*2 genotype: First experience in patients. Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US J THROMB HAEMOST 2009 8 1 43-53
40. Clopidogrel and prasugrel prolong primary hemostasis in the mouse beyond levels associated with P2Y12 inhibition. Andre P, DeGuzman F, Mills S, Pak Y, Inagaki M, Pandey A, Hollenbach S, Phillips D, Conley P J THROMB HAEMOST 2009 7 2 Abs AS-TH-022
41. Mechanisms of disease: Platelet activation and atherothrombosis. Davi G, Patrono C N ENGL J MED 2007 357 24 2482-2494 (Pubitemid 350272787)
42. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR et al ARTERIOSCLER THROMB VASC BIOL 2009 29 4 449-457
43. Central role of the P2Y12 receptor in platelet activation. Dorsam RT, Kunapuli SP J CLIN INVEST 2004 113 3 340-345
44. Differential effects of anti-platelet drugs on thrombus formation and stability. Stephens G, Gao D, Phillips DR, Andre P J THROMB HAEMOST 2007 5 Suppl 2 Abs O-W-034
45. The clopidogrel-insensitive pool of P2Y12 receptors exposed upon platelet activation contributes to thrombus formation and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor. Haberstock-Debic H, Andre P, Delaney S, Mills S, Pak Y, Phillips D, Conley P EUR HEART J 2009 30 Suppl Abs 5115
46. First in patient experience with a new, direct acting, reversible P2Y12 inhibitor, elinogrel (PRT060128): Evaluation in patients with high platelet reactivity during clopidogrel therapy. Gurbel PA, Bliden KP, Antonino MJ, Andre P, Sephens G, Gretler DD, Jurek MM, Hutchaleelaha A, Conley PB, Tantry US EUR HEART J 2009 30 Suppl Abs 2678
47. Intravenous platelet blockade with cangrelor during PCI. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr et al N ENGL J MED 2009 361 24 2330-2341
48. Platelet inhibition with cangrelor in patients undergoing PCI. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG et al N ENGL J MED 2009 361 24 2318-2329
49. ADP-mediated aggregation as a pharmacodynamic assay underestimates the antithrombotic activity of elinogrel, a competitive, reversible P2Y12 inhibitor, relative to clopidogrel. Conley PB, Andre P, Stephens G, Haberstock-Debic H, Jurek M, Gretler D, Phillips DR J THROMB HAEMOST 2009 7 2 Abs PP-TH-027
50. Initial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2Y12 inhibitor. Lieu HD, Conley PB, Andre P, Leese PT, Romanko K, Phillips DR, Jurek M, Meloni A, Hutchaleelaha A, Gretler DD J THROMB HAEMOST 2007 5 2 Abs P-T-292
51. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Baigent C, Sudlow C, Collins R, Peto R, Antithromboci TC BR MED J 2002 324 7329 71-86
52. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The early rapid reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trial. Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL et al AM HEART J 2009 158 6 998-1004.e1
53. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The onset/offset study. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ et al Circulation 2009 120 25 2577-2585
54. Metabolism and excretion of PRT060128, a new directacting, reversible P2Y12 inhibitor, in healthy human subjects. Desai M, Gretler D, Gu Z-M, Hutchaleelaha A, Kissling J, Lambing JL, Liu HD, Romanko K, Ye C ABS ANN MEET EXPOSITION AM ASSOC PHARM SCIENTISTS 2008 Abs T3312